246 related articles for article (PubMed ID: 24602808)
1. Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.
Hodgson RA; Mullins D; Lu SX; Guzzi M; Zhang X; Bleickardt CJ; Scott JD; Miller MW; Stamford AW; Parker EM; Varty GB
Eur J Pharmacol; 2014 May; 730():157-63. PubMed ID: 24602808
[TBL] [Abstract][Full Text] [Related]
2. Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.
Iijima M; Yoshimizu T; Shimazaki T; Tokugawa K; Fukumoto K; Kurosu S; Kuwada T; Sekiguchi Y; Chaki S
Br J Pharmacol; 2014 Jul; 171(14):3511-25. PubMed ID: 24654684
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression.
Hodgson RA; Higgins GA; Guthrie DH; Lu SX; Pond AJ; Mullins DE; Guzzi MF; Parker EM; Varty GB
Pharmacol Biochem Behav; 2007 Mar; 86(3):431-40. PubMed ID: 17291571
[TBL] [Abstract][Full Text] [Related]
4. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
Griebel G; Simiand J; Serradeil-Le Gal C; Wagnon J; Pascal M; Scatton B; Maffrand JP; Soubrie P
Proc Natl Acad Sci U S A; 2002 Apr; 99(9):6370-5. PubMed ID: 11959912
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior.
Bleickardt CJ; Mullins DE; Macsweeney CP; Werner BJ; Pond AJ; Guzzi MF; Martin FD; Varty GB; Hodgson RA
Psychopharmacology (Berl); 2009 Mar; 202(4):711-8. PubMed ID: 18923820
[TBL] [Abstract][Full Text] [Related]
6. Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models.
Gupta D; Radhakrishnan M; Thangaraj D; Kurhe Y
Eur J Pharmacol; 2014 Jul; 735():59-67. PubMed ID: 24747753
[TBL] [Abstract][Full Text] [Related]
7. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.
Griebel G; Stemmelin J; Gal CS; Soubrié P
Curr Pharm Des; 2005; 11(12):1549-59. PubMed ID: 15892661
[TBL] [Abstract][Full Text] [Related]
8. Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415.
Stemmelin J; Lukovic L; Salome N; Griebel G
Neuropsychopharmacology; 2005 Jan; 30(1):35-42. PubMed ID: 15367924
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
Dawson LA; Hughes ZA; Starr KR; Storey JD; Bettelini L; Bacchi F; Arban R; Poffe A; Melotto S; Hagan JJ; Price GW
Neuropharmacology; 2006 Jun; 50(8):975-83. PubMed ID: 16581092
[TBL] [Abstract][Full Text] [Related]
10. Effect of Vasopressin V1b Receptor Blockade on Activity of the Hypothalamic-Pituitary-Adrenal Axis in Old Monkeys with Depression-Like and Anxious Behavior Subjected to Stress or Injected with Vasopressin.
Goncharova ND; Chigarova OA; Oganyan TE
Bull Exp Biol Med; 2018 Nov; 166(1):86-91. PubMed ID: 30450521
[TBL] [Abstract][Full Text] [Related]
11. Vasopressin V1B Receptor Antagonists as Potential Antidepressants.
Chaki S
Int J Neuropsychopharmacol; 2021 Jul; 24(6):450-463. PubMed ID: 33733667
[TBL] [Abstract][Full Text] [Related]
12. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression.
Wesołowska A; Nikiforuk A
Neuropharmacology; 2007 Apr; 52(5):1274-83. PubMed ID: 17320917
[TBL] [Abstract][Full Text] [Related]
13. Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression.
Kassai F; Schlumberger C; Kedves R; Pietraszek M; Jatzke C; Lendvai B; Gyertyán I; Danysz W
Behav Pharmacol; 2012 Aug; 23(4):397-406. PubMed ID: 22785385
[TBL] [Abstract][Full Text] [Related]
14. Long-term anxiolytic and antidepressant-like behavioural effects of tiagabine, a selective GABA transporter-1 (GAT-1) inhibitor, coincide with a decrease in HPA system activity in C57BL/6 mice.
Thoeringer CK; Erhardt A; Sillaber I; Mueller MB; Ohl F; Holsboer F; Keck ME
J Psychopharmacol; 2010 May; 24(5):733-43. PubMed ID: 19346277
[TBL] [Abstract][Full Text] [Related]
15. Vasopressin in health and disease with a focus on affective disorders.
Zelena D
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):286-303. PubMed ID: 22954353
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant-like and anxiolytic-like effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa).
Zhang LM; Zhao N; Guo WZ; Jin ZL; Qiu ZK; Chen HX; Xue R; Zhang YZ; Yang RF; Li YF
Neuropharmacology; 2014 Jun; 81():116-25. PubMed ID: 24067925
[TBL] [Abstract][Full Text] [Related]
17. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor.
Chaki S; Hirota S; Funakoshi T; Suzuki Y; Suetake S; Okubo T; Ishii T; Nakazato A; Okuyama S
J Pharmacol Exp Ther; 2003 Feb; 304(2):818-26. PubMed ID: 12538838
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat.
Overstreet DH; Griebel G
Pharmacol Biochem Behav; 2005 Sep; 82(1):223-7. PubMed ID: 16181667
[TBL] [Abstract][Full Text] [Related]
19. Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action.
Andreasen JT; Fitzpatrick CM; Larsen M; Skovgaard L; Nielsen SD; Clausen RP; Troelsen K; Pickering DS
Brain Res; 2015 Mar; 1601():117-26. PubMed ID: 25578259
[TBL] [Abstract][Full Text] [Related]
20. The vasopressin V1b receptor as a therapeutic target in stress-related disorders.
Griebel G; Simiand J; Stemmelin J; Gal CS; Steinberg R
Curr Drug Targets CNS Neurol Disord; 2003 Jun; 2(3):191-200. PubMed ID: 12769799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
